Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03315741 · ClinicalTrials.gov registry record · Phase 1
The Safety and Tolerability of Pirfenidone for BOS After HCT
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03315741: Completed Phase 1 study, sponsored by Stanford University.
NCT03315741 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03315741, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a phase 1, non-randomized, single-arm, open label, single center clinical trial to determine the tolerability and safety of pirfenidone in patients with BOS associated with lung GVHD after hematopoietic cell transplant.
Interventions
- DRUG Pirfenidone 267 MG [Esbriet]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2022-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03315741
The ClinicalTrials.gov registry entry for NCT03315741 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pirfenidone 267 MG [Esbriet] is the first listed.
NCT03315741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03315741 about?
NCT03315741 is a clinical study titled "The Safety and Tolerability of Pirfenidone for BOS After HCT". This is a phase 1, non-randomized, single-arm, open label, single center clinical trial to determine the tolerability and safety of pirfenidone in patients with BOS associated with lung GVHD after hematopoietic cell transplant.
What is the current status of trial NCT03315741?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-03-01. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT03315741?
The interventions under investigation include: Pirfenidone 267 MG [Esbriet] (DRUG).
Who is sponsoring clinical trial NCT03315741?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.